Gilead Sciences logo
GILDGilead Sciences
Trade GILD now
Gilead Sciences primary media

About Gilead Sciences

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company specializes in several therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, cardiovascular, and inflammation/respiratory diseases. Gilead is committed to advancing healthcare by addressing unmet medical needs and improving life outcomes for patients around the globe. Their operations span research and development, manufacturing, and the commercialization of their products in various countries. Through collaborations and partnerships, Gilead aims to accelerate the development of novel therapies and expand its product portfolio to make a significant impact in the realm of healthcare.

What is GILD known for?

Snapshot

Public US
Ownership
1987
Year founded
14488
Employees
Foster City, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Gilead Sciences

  • HIV/AIDS antiretroviral medications, providing life-saving treatments to millions globally.
  • Hepatitis C treatments, significantly improving cure rates for patients.
  • COVID-19 treatment Remdesivir, used globally to treat severe cases.
  • CAR T-cell therapies for certain types of blood cancer, offering innovative treatment options.
  • Hepatitis B medications, managing chronic infections and reducing health complications.
  • HIV PrEP (Pre-exposure Prophylaxis), reducing the risk of HIV infection in high-risk populations.

Gilead Sciences executive team

  • Mr. Daniel P. O'DayChairman & CEO
  • Mr. Andrew D. DickinsonChief Financial Officer
  • Ms. Johanna MercierChief Commercial & Corporate Affairs Officer
  • Ms. Erin BurkhartSVP, Controller & Principal Accounting Officer
  • Ms. Jacquie Ross C.F.A.Senior Vice President of Treasury and Investor Relations
  • Ms. Keeley WettanExecutive VP and General Counsel of Legal & Compliance
  • Ms. Jyoti K. MehraExecutive Vice President of Human Resources
  • Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & Portfolio
  • Dr. Flavius Martin M.D.Executive Vice President of Research
  • Ms. Janet DorlingSenior Vice President of Intercontinental Region & Global Patient Solutions

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.